Unveiling the Silent Threat: The Escalation and Defence Against Antibiotic Resistance

Year : 2025 | Volume : 02 | Issue : 02 | Page :
    By

    Swapnesh Bhaduri,

  1. Student, Department of Pharmacy, National Institute of Pharmaceutical Education and Research, Kolkata, West Bengal, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_200780’);});Edit Abstract & Keyword

The global challenge of antibiotic resistance presents a significant risk to public health, driven by multifaceted factors worldwide. This issue, akin to the impacts of climate change, requires concerted efforts at national and international levels to mitigate its consequences. Antibiotics have revolutionized modern medicine, enabling critical interventions like surgeries, transplants, and cancer treatments. However, without global collaboration, we face significant setbacks across medical, social, and economic domains. Initiatives to address resistance have resulted in numerous reports advocating for reduced antimicrobial prescribing, yet evidence supporting their efficacy remains limited. Specific microorganisms, such as Escherichia coli, are displaying increased resilience, underscoring the necessity for prudent antibiotic utilization and investigation of substitutes. Recent metagenomic studies examining ancient DNA from permafrost sediments reveal the natural occurrence of antibiotic resistance genes predating modern antibiotic use. This discovery challenges the notion that resistance is solely a modern phenomenon driven by antibiotic pressures. Bacterial pathogens pose a significant public health threat, with multidrug-resistant organisms emerging in healthcare and community settings. Improper antibiotic use exacerbates environmental contamination and fosters drug-resistant strains, posing threats to human health. Electrochemical sensors offer promising avenues for detecting antibiotic contamination, with advancements enhancing sensitivity. Urgent endeavors are needed to develop novel antimicrobial agents or alternative therapies to combat multidrug-resistant bacteria. This review explores the evolution of resistant bacteria, elucidating mechanisms and potential avenues for prevention and treatment.

Keywords: Resistance, discovery, pathogens, innovations, challenges

[This article belongs to International Journal of Antibiotics ]

How to cite this article:
Swapnesh Bhaduri. Unveiling the Silent Threat: The Escalation and Defence Against Antibiotic Resistance. International Journal of Antibiotics. 2025; 02(02):-.
How to cite this URL:
Swapnesh Bhaduri. Unveiling the Silent Threat: The Escalation and Defence Against Antibiotic Resistance. International Journal of Antibiotics. 2025; 02(02):-. Available from: https://journals.stmjournals.com/ijab/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_200780’);});Edit

References

  1. Terreni M, Taccani M, Pregnolato M. New antibiotics for multidrug-resistant bacterial strains: Latest research developments and future perspectives. Molecules. 2021 May 2;26(9). doi:10.3390/molecules26092671.
  2. Cals JWL, Boumans D, Lardinois RJM, et al. Public beliefs on antibiotics and respiratory tract infections: An internet-based questionnaire study. 2007 [cited 2025 Jul 22]. Available from: https://cbs.nl.
  3. Colman AM, Krockow EM, Chattoe-Brown E, Tarrant C. Medical prescribing and antibiotic resistance: A game-theoretic analysis of a potentially catastrophic social dilemma. PLoS One. 2019 Apr;14(4):e0215480. doi:10.1371/journal.pone.0215480.
  4. Tarrant C, Krockow EM, Nakkawita WMID, et al. Optimizing antibiotic prescribing: Collective approaches to managing a common-pool resource. Clin Microbiol Infect. 2019 Nov;25(11):1356–1363. doi:10.1016/j.cmi.2019.03.008.
  5. Krockow EM, Cheng KO, Maltby J, McElroy E. Existing terminology related to antimicrobial resistance fails to evoke risk perceptions and be remembered. Commun Med. 2023 Oct;3(1):149. doi:10.1038/s43856-023-00379-6.
  6. McCullough AR, Parekh S, Rathbone J, Del Mar CB, Hoffmann TC. A systematic review of the public’s knowledge and beliefs about antibiotic resistance. J Antimicrob Chemother. 2016 Jan;71(1):27–33. doi:10.1093/jac/dkv310.
  7. Brookes-Howell L, Elwyn G, Hood K, et al. ‘The body gets used to them’: Patients’ interpretations of antibiotic resistance and the implications for containment strategies. J Gen Intern Med. 2012 Jul;27(7):766–772. doi:10.1007/s11606-011-1916-1.
  8. Govindan B. Bacterial Survivor: An Interactive Game that Combats Misconceptions about Antibiotic Resistance. J Microbiol Biol Educ. 2018 Jan;19(3). doi:10.1128/jmbe.v19i3.1675.
  9. Gualano MR, Gili R, Scaioli G, Bert F, Siliquini R. General population’s knowledge and attitudes about antibiotics: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2015 Jan;24(1):2–10. doi:10.1002/pds.3716.
  10. Shahpawee NS, Chaw LL, Muharram SH, Goh HP, Hussain Z, Ming LC. University students’ antibiotic use and knowledge of antimicrobial resistance: What are the common myths? Antibiotics. 2020 Jun;9(6):349. doi:10.3390/antibiotics9060349.
  11. Huttner B, Goossens H, Verheij T, Harbarth S. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet Infect Dis. 2010 Jan;10(1):17–31. doi:10.1016/S1473-3099(09)70305-6.
  12. Hughes JM. Preserving the lifesaving power of antimicrobial agents. JAMA. 2011 Mar 9;305(10):1027–1028. doi:10.1001/jama.2011.279.
  13. Hawkings NJ, Wood F, Butler CC. Public attitudes towards bacterial resistance: A qualitative study. J Antimicrob Chemother. 2007 Jun;59(6):1155–1160. doi:10.1093/jac/dkm103.
  14. Brooks L, Shaw A, Sharp D, Hay AD. Towards a better understanding of patients’ perspectives of antibiotic resistance and MRSA: A qualitative study. Fam Pract. 2008;25(5):341–348. doi:10.1093/fampra/cmn037.
  15. McNulty CAM, Nichols T, Boyle PJ, Woodhead M, Davey P. The English antibiotic awareness campaigns: Did they change the public’s knowledge of and attitudes to antibiotic use? J Antimicrob Chemother. 2010 May;65(7):1526–1533. doi:10.1093/jac/dkq126.
  16. Simpson SA, Wood F, Butler CC. General practitioners’ perceptions of antimicrobial resistance: A qualitative study. J Antimicrob Chemother. 2007 Feb;59(2):292–296. doi:10.1093/jac/dkl467.
  17. Srinivasan A, Song X, Richards A, et al. A Survey of Knowledge, Attitudes, and Beliefs of House Staff Physicians From Various Specialties Concerning Antimicrobial Use and Resistance. [cited 2025 Jul 22]. Available from: https://archinte.jamanetwork.com/.
  18. Holmes AH, Moore LSP, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016 Jan 9;387(10014):176–187. doi:10.1016/S0140-6736(15)00473-0.
  19. Huijbers PMC, Blaak H, De Jong MCM, Graat EAM, Vandenbroucke-Grauls CMJE, De Roda Husman AM. Role of the environment in the transmission of antimicrobial resistance to humans: A review. Environ Sci Technol. 2015 Oct;49(20):11993–12004. doi:10.1021/acs.est.5b02566.
  20. Woolhouse MEJ, Ward MJ. Sources of antimicrobial resistance. Science. 2013 Sep;341(6153):1460–1461. doi:10.1126/science.1243444.
  21. Burow E, Käsbohrer A. Risk factors for antimicrobial resistance in Escherichia coli in pigs receiving oral antimicrobial treatment: A systematic review. Microb Drug Resist. 2017 Mar;23(2):194–205. doi:10.1089/mdr.2015.0318.
  22. Marti E, Variatza E, Balcazar JL. The role of aquatic ecosystems as reservoirs of antibiotic resistance. Trends Microbiol. 2014 Jan;22(1):36–41. doi:10.1016/j.tim.2013.11.001.
  23. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet. 2005 Feb;365:579–587.
  24. Fleming A. Penicillin, its practical application. Br J Surg. 1946;3:222.
  25. Hranjec T, Lehman SM, Samuel J, et al. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected ICU-acquired infection: A quasi-experimental, before and after observational cohort study. Lancet Infect Dis. 2012 Oct;12(10):774–780. doi:10.1016/S1473-3099(12)70151-2.
  26. S. Food and Drug Administration. 2010 Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals. 2014.
  27. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013 Dec;13(12):1057–1098. doi:10.1016/S1473-3099(13)70318-9.
  28. Thriemer K, Katuala Y, Batoko B, et al. Antibiotic prescribing in DR Congo: A knowledge, attitude and practice survey among medical doctors and students. PLoS One. 2013 Feb;8(2):e55495. doi:10.1371/journal.pone.0055495.
  29. Walker J, Heaney AK, Buehler SS, et al. Assessing the global risk of typhoid outbreaks caused by extensively drug resistant Salmonella Typhi. Nat Commun. 2023 Dec;14(1). doi:10.1038/s41467-023-42353-9.
  30. Walker MS, Walker JB. Streptomycin biosynthesis and metabolism. J Biol Chem. 1970 Dec;245(24):6683–6689. doi:10.1016/s0021-9258(18)62588-8.
  31. Mak S, Xu Y, Nodwell JR. The expression of antibiotic resistance genes in antibiotic-producing bacteria. Mol Microbiol. 2014;93(3):391–402. doi:10.1111/mmi.12689.
  32. Shinkawa H, Sugiyama M, Nimi O, Nomi R. Molecular cloning and expression in Streptomyces lividans of a streptomycin G-phosphotransferase gene from a streptomycin-producing microorganism: The gene encoding streptomycin 6-kinase involved in self-resistance. 2285.
  33. Martínez JL. Ecology and evolution of chromosomal gene transfer between environmental microorganisms and pathogens. Microbiol Spectr. 2018;6(1). doi:10.1128/microbiolspec.mtbp-0006-2016.
  34. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. 1993.
  35. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2). doi:10.1128/microbiolspec.VMBF-0016-2015.
  36. Guilfoile PG, Hutchinson CR. A bacterial analog of the mdr gene of mammalian tumor cells is present in Streptomyces peucetius, the producer of daunorubicin and doxorubicin. Proc Natl Acad Sci U S A. 1991 [cited 2021 May 1]. Available from: https://www.pnas.org.
  37. Yoon R, Chang K, Nang SC, Chan HK, Li J. Novel antimicrobial agents for combating antibiotic-resistant bacteria. 2022.
  38. Chufan EE, Sim HM, Ambudkar SV. Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): Recent biochemical and structural studies. In: Advances in Cancer Research. Vol. 125. Academic Press Inc.; 2015. p. 71–96. doi:10.1016/bs.acr.2014.10.003.
  39. Brown K, Li W, Kaur P. Role of aromatic and negatively charged residues of DrrB in multisubstrate specificity conferred by the DrrAB system of Streptomyces peucetius. Biochemistry. 2017;56(13):1921–31. doi:10.1021/acs.biochem.6b01155.
  40. Szewczyk P, Tao H, McGrath AP, et al. Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein. Acta Crystallogr D Biol Crystallogr. 2015;71:732–41. doi:10.1107/S1399004715000978.
  41. Sugiyama M, Kumagai T. Review: Molecular and structural biology of bleomycin and its resistance determinants. 2002.
  42. Rudolf JD, Dong L-B, Huang T, Shen B. Crystal structure of the zorbamycin-binding protein ZbmA, the primary self-resistance element in Streptomyces flavoviridis Biochemistry. 2015;54(45):6842–51. doi:10.1021/acs.biochem.5b01008.
  43. Du L, Sánchez C, Chen M, Edwards DJ, Shen B. The biosynthetic gene cluster for the antitumor drug bleomycin from Streptomyces verticillus ATCC15003 supporting functional interactions between nonribosomal peptide synthetases and a polyketide synthase. 2000.
  44. Pozzi R, Maffioli S, Sosio M, Donadio S. Distinct mechanisms contribute to immunity in the lantibiotic NAI-107 producer strain Microbispora ATCC PTA-5024. Environ Microbiol. 2016;18(1):118–32. doi:10.1111/1462-2920.12892.
  45. Corin Y, Robert FD, Bateman A. The PASTA domain: a β-lactam-binding domain. Trends Biochem Sci. 2002;27:438–40.
  46. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37(1):177–92. doi:10.1016/j.biotechadv.2018.11.013.
  47. Ogawara H. Self-resistance in Streptomyces, with special reference to β-lactam antibiotics. Molecules. 2016;21(5). doi:10.3390/molecules21050605.
  48. Yoon R, Chang K, Nang SC, Chan HK, Li J. Novel antimicrobial agents for combating antibiotic-resistant bacteria. 2022.
  49. Binda E, Marcone GL, Berini F, Pollegioni L, Marinelli F. Streptomyces as efficient expression system for a D,D-peptidase/D,D-carboxypeptidase involved in glycopeptide antibiotic resistance. BMC Biotechnol. 2013;13:24. doi:10.1186/1472-6750-13-24.
  50. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51. doi:10.1038/nrmicro3380.
  51. Binda E, Marcone GL, Berini F, Pollegioni L, Marinelli F. Streptomyces as efficient expression system for a D,D-peptidase/D,D-carboxypeptidase involved in glycopeptide antibiotic resistance. BMC Biotechnol. 2013;13:24. doi:10.1186/1472-6750-13-24.
  52. World Health Assembly. Global action plan on antimicrobial resistance. 2015 [cited 2021 May 1]. Available from: https://www.who.int/antimicrobial-resistance/global-action-plan/en/.
  53. Knowles JR. Penicillin resistance: The chemistry of β-lactamase inhibition. Acc Chem Res. 1985;18(4):97–104.
  54. Rehman A, Patrick WM, Lamont IL. Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: New approaches to an old problem. J Med Microbiol. 2019;68(1):1–10.
  55. Peacock SJ, Paterson GK. Mechanisms of methicillin resistance in Staphylococcus aureus. Annu Rev Biochem. 2015;84:577–601.
  56. Roberts MC. Tetracycline resistance determinants: Mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev. 1996;19(1):1–24.
  57. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother. 1995;39(3):577–85.
  58. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006;42(Suppl_1):S25–34.
  59. Sutcliffe JG. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc Natl Acad Sci U S A. 1978;75(8):3737–41.
  60. Gomes C, Ruiz-Roldán L, Mateu J, Ochoa TJ, Ruiz J. Azithromycin resistance levels and mechanisms in Escherichia coli. Sci Rep. 2019;9(1):6089.
  61. Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama SI, Watanabe H, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis. 2011 Jan;17(1):148.
  62. Patterson JE, Zervos MJ. High-level gentamicin resistance in Enterococcus: microbiology, genetic basis, and epidemiology. Rev Infect Dis. 1990 Jul 1;12(4):644–52.
  63. Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodríguez MC, Velasco M, et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents. 2008 Dec 1;32(6):534–7.
  64. Patel SN, Memari N, Shahinas D, Toye B, Jamieson FB, Farrell DJ. Linezolid resistance in Enterococcus faecium isolated in Ontario, Canada. Diagn Microbiol Infect Dis. 2013 Dec 1;77(4):350–3.
  65. Telenti A, Imboden P, Marchesi F, Matter L, Schopfer K, Bodmer T, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993 Mar 13;341(8846):647–51.
  66. Eliopoulos GM, Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis. 2001 Jun 1;32(11):1608–14.
  67. Drinkovic D, Fuller ER, Shore KP, Holland DJ, Ellis-Pegler R. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother. 2001 Aug 1;48(2):315–6.
  68. Huovinen PE. Trimethoprim resistance. Antimicrob Agents Chemother. 1987 Oct;31(10):1451–6.
  69. Lartigue MF, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P. Ertapenem resistance of Escherichia coli. Emerg Infect Dis. 2007 Feb;13(2):315.
  70. Suárez JE, Mendoza MC. Plasmid-encoded fosfomycin resistance. Antimicrob Agents Chemother. 1991 May;35(5):791–5.
  71. He T, Wang R, Liu D, Walsh TR, Zhang R, Lv Y, et al. Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat Microbiol. 2019 Sep;4(9):1450–6.
  72. Kempf I, Jouy E, Chauvin C. Colistin use and colistin resistance in bacteria from animals. Int J Antimicrob Agents. 2016 Dec 1;48(6):598–606.
  73. European Centre for Disease Prevention and Control. Systematic Review and Evidence-Based Guidance on Perioperative Antibiotic Prophylaxis. Stockholm: ECDC; 2013 [cited 2021 May 1]. Available from: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Perioperative%20antibiotic%20prophylaxis%20-%20June%202013.pdf.
  74. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018. Atlanta: U.S. Department of Health and Human Services; 2018 [cited 2021 May 1]. Available from:

https://www.cdc.gov/std/stats18/STDSurveillance2018-full-report.pdf.

  1. Bradford PA, Miller AA, O’Donnell J, Mueller JP. Zoliflodacin: An oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrhoeae. ACS Infect Dis. 2020;6:1332–45.
  2. Kowalska-Krochmal B, Dudek-Wicher R. The minimum inhibitory concentration of antibiotics: Methods, interpretation, clinical relevance. Pathogens. 2021;10:165.
  3. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88–9.
  4. Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Heguy A, Nault V, Valiquette L. Clinical and healthcare burden of multiple recurrences of Clostridium difficile Clin Infect Dis. 2016;62:574–80.
  5. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the IDSA and SHEA. Clin Infect Dis. 2018;66:987–94.
  6. Debast SB, Bauer MP, Kuijper EJ. Update of the treatment guidance document for Clostridium difficile Clin Microbiol Infect. 2014;20(Suppl 2):1–26.
  7. World Health Organization. Antibacterial agents in clinical development: An analysis of the antibacterial clinical development pipeline. Geneva: WHO; 2019 [cited 2024 Mar 7]. Available from: http://apps.who.int/iris/bitstream/handle/10665/258965/WHO-EMP-IAU-2017.11-eng.pdf.
  8. Sartelli M, Chichom-Mefire A, Labricciosa FM, Hardcastle T, Abu-Zidan FM, Adesunkanmi AK, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines. World J Emerg Surg. 2017;12:29.
  9. Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15:1516–8.
  10. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20:1170–5.
  11. Katz ML, Mueller LV, Polyakov M, Weinstock SF. Where have all the antibiotic patents gone? Nat Biotechnol. 2006;24:1529–31.
  12. TB Alliance. Pretomanid: A new hope for highly drug-resistant tuberculosis [Internet]. Available from:https://www.tballiance.org/news/pretomanid-new-hope-highly-drug-resistant-tuberculosis [cited 2024 Mar 7].
  1. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. doi:10.1056/NEJMoa1901814.
  2. US Food and Drug Administration. Pretomanid [Internet]. Available from:https://www.fda.gov/drugs/development-approval-process-drugs/pretomanid [cited 2024 Mar 7].
  1. Kraus CN. Low hanging fruit in infectious disease drug development. Curr Opin Microbiol. 2008;11:434–8.
  2. Projan SJ. Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003;6:427–30.
  3. Projan SJ, Shlaes DM. Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect. 2004;10(Suppl 4):18–22.
  4. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38:1279–86.
  5. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science. 2009;325:1089.
  6. Walsh C. Where will new antibiotics come from? Nat Rev Microbiol. 2003;1:65–70.
Regular Issue Subscription Review Article
Volume 02
Issue 02
Received 20/01/2025
Accepted 22/07/2025
Published 26/07/2025
Publication Time 187 Days
73

[first_name] [last_name]

My IP

PlumX Metrics